What is Edgewise Therapeutics Inc?
, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.37B, and a P/E ratio of 4.8x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 25,296 shares $241k | 0 |
| 3-6months | 1840,590 shares $1.8M | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |